Teratogenicity with olanzapine

Indian Journal of Psychological Medicine

Volumn 36, Issue 1, 2014, Pages 91-93

  Prakash, Sathya ^a   Chadda, Rakesh ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Olanzapine; pregnancy; teratogenicity

Indexed keywords

EID: 84894777605     PISSN: 02537176     EISSN: 09751564     Source Type: Journal    
DOI: 10.4103/0253-7176.127266     Document Type: Article

References (11)

1. World Health Organisation. The International Statistical Classification of Diseases and Related Health Problems. 10th ed.,Geneva: World Health Organization; 1992.
2. World Health Organization. WHO Child Growth Standards: Growth Velocity Based on Weight, Height and Head Circumference. Geneva: World Health Organization; 2009.
3. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
4. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, et al. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J Clin Psychiatry 2005;66:444-9.
5. Arora M, Praharaj SK. Meningocele and ankyloblepharon following in utero exposure to olanzapine. Eur Psychiatry 2006;21:345-6.
6. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28:279-88.
7. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: Early experience. J Clin Psychopharmacol 2000;20:399-403.
8. Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, et al. Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. Am J Psychiatry 2007;164:1214-20.
9. Ramkisson R, Campbell M, Agius M. The clinical dilemma-Prescribing in pregnancy. Psychiatr Danub 2008;20:88-90.
10. Kirchheiner J, Berghöfer A, Bolk-Weischedel D. Healthy outcome under olanzapine treatment in a pregnant woman. Pharmacopsychiatry 2000;33:78-80.
11. Donohoe DR, Aamodt EJ, Osborn E, Dwyer DS. Antipsychotic drugs disrupt normal development in Caenorhabditis elegans via additional mechanisms besides dopamine and serotonin receptors. Pharmacol Res 2006;54:361-72.